REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
“We are pleased to report the first clinical data for RMC-9805, our novel, oral RAS (ON) G12D-selective covalent inhibitor, which demonstrate encouraging initial safety, tolerability and antitumor ...
REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback